Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series

Lalit Verma ,1 Mithun Thulasidas ,1 Avnindra Gupta 1 1 Centre for Sight, Delhi 110029, IndiaCorrespondence: Lalit Verma; Mithun ThulasidasCentre for Sight, B-5/24, Safdarjung Enclave, Delhi 110029, IndiaEmail lalitverma@yahoo.com; mithun.thulasidas@gmail.comPurpose: To report a case series of four...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Verma L, Thulasidas M, Gupta A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	toxoplasmosis toxoplasmic retinochoroiditis intravitreal clindamycin uveitis vitritis Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/55056b1b48d94708a0924551e3ae9d87
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:55056b1b48d94708a0924551e3ae9d87
record_format	dspace
spelling	oai:doaj.org-article:55056b1b48d94708a0924551e3ae9d872021-12-02T15:18:25ZIntravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series1177-5483https://doaj.org/article/55056b1b48d94708a0924551e3ae9d872020-12-01T00:00:00Zhttps://www.dovepress.com/intravitreal-clindamycin-as-first-line-therapy-for-toxoplasmic-retinoc-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Lalit Verma ,1 Mithun Thulasidas ,1 Avnindra Gupta 1 1 Centre for Sight, Delhi 110029, IndiaCorrespondence: Lalit Verma; Mithun ThulasidasCentre for Sight, B-5/24, Safdarjung Enclave, Delhi 110029, IndiaEmail lalitverma@yahoo.com; mithun.thulasidas@gmail.comPurpose: To report a case series of four ocular toxoplasmosis patients who received intravitreal clindamycin as first-line treatment.Materials and Methods: Retrospective interventional case series.Results: Four (two females and two males) patients were diagnosed with active primary toxoplasmic retinochoroiditis based on their clinical presentation. All patients received intravitreal clindamycin 1mg/0.1mL as first-line therapy (two injections with 1-week interval). Oral corticosteroid 1mg/kg/day was also given in a tapering fashion over 4– 6 weeks. A remarkable response was seen in all cases with improved visual acuity, sharpening of the lesion borders, and resolution of inflammation within 4– 6 weeks. No recurrence or reactivation was noted until 2 years follow-up.Conclusion: Intravitreal clindamycin, combined with oral corticosteroids, can be considered an effective and safe first-line therapy for active toxoplasmic retinochoroiditis. It provides the patient a more convenience, safer systemic side effect profile, increased availability, and fewer follow-up visits and hematologic investigations.Keywords: toxoplasmosis, toxoplasmic retinochoroiditis, intravitreal clindamycin, uveitis, vitritisVerma LThulasidas MGupta ADove Medical Pressarticletoxoplasmosistoxoplasmic retinochoroiditisintravitreal clindamycinuveitisvitritisOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 4279-4285 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	toxoplasmosis toxoplasmic retinochoroiditis intravitreal clindamycin uveitis vitritis Ophthalmology RE1-994
spellingShingle	toxoplasmosis toxoplasmic retinochoroiditis intravitreal clindamycin uveitis vitritis Ophthalmology RE1-994 Verma L Thulasidas M Gupta A Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series
description	Lalit Verma ,1 Mithun Thulasidas ,1 Avnindra Gupta 1 1 Centre for Sight, Delhi 110029, IndiaCorrespondence: Lalit Verma; Mithun ThulasidasCentre for Sight, B-5/24, Safdarjung Enclave, Delhi 110029, IndiaEmail lalitverma@yahoo.com; mithun.thulasidas@gmail.comPurpose: To report a case series of four ocular toxoplasmosis patients who received intravitreal clindamycin as first-line treatment.Materials and Methods: Retrospective interventional case series.Results: Four (two females and two males) patients were diagnosed with active primary toxoplasmic retinochoroiditis based on their clinical presentation. All patients received intravitreal clindamycin 1mg/0.1mL as first-line therapy (two injections with 1-week interval). Oral corticosteroid 1mg/kg/day was also given in a tapering fashion over 4– 6 weeks. A remarkable response was seen in all cases with improved visual acuity, sharpening of the lesion borders, and resolution of inflammation within 4– 6 weeks. No recurrence or reactivation was noted until 2 years follow-up.Conclusion: Intravitreal clindamycin, combined with oral corticosteroids, can be considered an effective and safe first-line therapy for active toxoplasmic retinochoroiditis. It provides the patient a more convenience, safer systemic side effect profile, increased availability, and fewer follow-up visits and hematologic investigations.Keywords: toxoplasmosis, toxoplasmic retinochoroiditis, intravitreal clindamycin, uveitis, vitritis
format	article
author	Verma L Thulasidas M Gupta A
author_facet	Verma L Thulasidas M Gupta A
author_sort	Verma L
title	Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series
title_short	Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series
title_full	Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series
title_fullStr	Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series
title_full_unstemmed	Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series
title_sort	intravitreal clindamycin as first-line therapy for toxoplasmic retinochoroiditis: a case series
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/55056b1b48d94708a0924551e3ae9d87
work_keys_str_mv	AT vermal intravitrealclindamycinasfirstlinetherapyfortoxoplasmicretinochoroiditisacaseseries AT thulasidasm intravitrealclindamycinasfirstlinetherapyfortoxoplasmicretinochoroiditisacaseseries AT guptaa intravitrealclindamycinasfirstlinetherapyfortoxoplasmicretinochoroiditisacaseseries
_version_	1718387446198042624

Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series

Ejemplares similares